• This record comes from PubMed

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

. 2023 Jun 01 ; 108 (6) : 1676-1679. [epub] 20230601

Language English Country Italy Media electronic

Document type Letter

Persistent link   https://www.medvik.cz/link/pmid36546416

See more in PubMed

Teras LR, DeSantis CE, Cerhan JR, et al. . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-459. PubMed

Else M, Dearden CE, Matutes E, et al. . Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740. PubMed

Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6):1918-1926. PubMed

Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15(1):184-186. PubMed

Chihara D, Arons E, Stetler-Stevenson M, et al. . Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021;5(23):4807-4816. PubMed PMC

Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114(21):4687-4695. PubMed PMC

Chihara D, Arons E, Stetler-Stevenson M, et al. . Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020;38(14):1527-1538. PubMed PMC

Chihara D, Kantarjian H, O'Brien S, et al. . Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016;174(5):760-766. PubMed PMC

Zinzani PL, Bonifazi F, Pellegrini C, et al. . Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin Lymphoma Myeloma Leuk. 2012;12(4):287-289. PubMed

Tiacci E, Park JH, De Carolis L, et al. . Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18):1733-1747. PubMed PMC

Tiacci E, De Carolis L, Simonetti E, et al. . Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021;384(19):1810-1823. PubMed

Kreitman RJ, Moreau P, Ravandi F, et al. . Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood. 2023;14(9):996-1006. PubMed PMC

Kreitman RJ, Dearden C, Zinzani PL, et al. . Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768-1777. PubMed PMC

Kreitman RJ, Dearden C, Zinzani PL, et al. . Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021;14(1):35. PubMed PMC

Kreitman RJ, Tallman MS, Robak T, et al. . Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018;131(21):2331-2334. PubMed PMC

Bohn JP, Neururer S, Pirklbauer M, Pircher A, Wolf D. Hairy cell leukemia patients have a normal life expectancy - a 35-year single-center experience and comparison with the general population. Cancers (Basel). 2022;14(5):1242. PubMed PMC

Find record

Citation metrics

Archiving options